US · KYMR
Kymera Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Watertown, MA 02472
- Website
- kymeratx.com
Price · as of 2025-12-31
$80.71
Market cap 7.31B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $52.11 | -35.44% |
| Intrinsic Value(DCF) | $42.98 | -46.75% |
| Graham-Dodd Method(GD) | $0.27 | -99.67% |
| Graham Formula(GF) | $29.30 | -63.7% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $56.10 | $148.45 | $808,478.57 | $1.25 | $0.00 |
| 2021 | $38.43 | $81.14 | $6.66 | $0.00 | $0.00 |
| 2022 | $29.59 | $31.67 | $5.21 | $0.00 | $74.95 |
| 2023 | $43.49 | $41.73 | $44.40 | $0.00 | $0.00 |
| 2024 | $32.89 | $30.47 | $5.52 | $0.00 | $90.45 |
| 2025 | $90.10 | $52.11 | $11.59 | $0.27 | $29.30 |
AI valuation
Our deep-learning model estimates Kymera Therapeutics, Inc.'s (KYMR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $52.11
- Current price
- $80.71
- AI upside
- -35.44%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$42.98
-46.75% upside
Graham-Dodd
$0.27
-99.67% upside
Graham Formula
$29.30
-63.7% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KYMR | Kymera Therapeutics, Inc. | $80.71 | 7.31B | -35% | -47% | -100% | -64% | -24.42 | 4.81 | 193.97 | -22.56 | -102.50 | 4.81 | 100.00% | -891.33% | -794.39% | -25.78% | -55.98% | -22.89% | 0.05 | -1403.21 | 10.47 | 10.19 | 0.91 | 2383.00% | -1672.00% | 1302.00% | -3.08% | -2.80 | -37.55% | 0.00% | 0.00% | 3.19% | -19.57 | -29.18 | 174.43 | 27.01 |
| AAPG | ASCENTAGE PHARMA GROUP IN… | $24.00 | 557.78M | -51% | -67% | — | — | -27.16 | 40.63 | 10.95 | -46.99 | — | 65.65 | 97.03% | -37.70% | -41.34% | -243.53% | -49.87% | -15.45% | 6.32 | -5.74 | 1.26 | 1.14 | -1.82 | -8979.00% | 34177.00% | -8267.00% | -1.26% | -0.10 | -18.30% | 0.00% | 0.00% | 2.74% | -30.20 | -82.32 | 11.39 | -0.29 |
| ACAD | ACADIA Pharmaceuticals In… | $24.56 | 4.16B | +74% | +42% | -54% | +114% | 12.85 | 3.97 | 3.04 | 22.02 | — | 4.75 | 91.46% | 24.10% | 23.64% | 38.89% | 513.41% | 23.39% | 0.07 | — | 2.38 | 2.18 | -2.67 | -46757.00% | 3185.00% | -77327.00% | 5.40% | 0.40 | 398.52% | 0.00% | 0.00% | 4.68% | 9.56 | 14.03 | 2.30 | 3.24 |
| ACLX | Arcellx, Inc. | $113.79 | 6.58B | -42% | — | — | — | -28.05 | — | — | -31.38 | -27.10 | — | 0.00% | — | — | -100.68% | 644.58% | -39.69% | — | -10.45 | — | — | 0.00 | 10350.00% | -10000.00% | 11938.00% | -3.31% | — | 541.60% | 0.00% | 0.00% | 0.02% | -25.37 | -30.21 | — | — |
| AKRO | Akero Therapeutics, Inc. | $54.65 | 4.5B | — | — | — | — | -11.22 | 3.77 | — | -7.43 | -37.70 | 3.77 | 0.00% | — | — | -39.22% | -1042.60% | -35.85% | 0.05 | -61.14 | 19.38 | 18.69 | 1.06 | 2976.00% | — | 5898.00% | -8.17% | -5.79 | -844.19% | 0.00% | 0.00% | 3.41% | -7.43 | -9.18 | — | 20.91 |
| CRNX | Crinetics Pharmaceuticals… | $41.10 | 4.21B | +36% | -54% | — | — | -8.22 | 3.86 | 705.95 | -6.17 | -24.08 | 3.86 | 80.15% | -9534.48% | -8585.18% | -40.17% | -2936.77% | -36.34% | 0.05 | — | 12.32 | 12.09 | 0.11 | 3415.00% | 42166.00% | 6695.00% | -10.03% | -4.44 | -2180.46% | 0.00% | 0.00% | 0.00% | -5.51 | -7.42 | 525.26 | 14.87 |
| IMVT | Immunovant, Inc. | $27.73 | 5.64B | — | — | — | — | -6.14 | 3.59 | — | -4.18 | -13.59 | 3.59 | 0.00% | — | — | -62.46% | 3667.16% | -57.36% | 0.00 | — | 11.16 | 10.42 | 1.63 | 4521.00% | — | 7552.00% | -14.82% | -5.47 | 3152.27% | 0.00% | 0.00% | 3.09% | -4.17 | -4.85 | — | 19.16 |
| NAMS | NewAmsterdam Pharma Compa… | $35.46 | 4.08B | +16% | -57% | — | +102% | — | 5.50 | 166.90 | -12.87 | — | 5.50 | 99.74% | -1002.90% | -905.74% | 0.00% | 1564.53% | 0.00% | 0.00 | — | 7.88 | 7.69 | 2.02 | -3164.00% | -5061.00% | -704.00% | -3.94% | -1.72 | 1026.20% | 0.00% | — | 0.00% | -13.82 | -21.07 | 138.63 | 24.84 |
| PRAX | Praxis Precision Medicine… | $336.75 | 7.12B | -61% | — | — | — | -24.53 | 8.47 | — | -22.57 | -76.60 | 8.47 | 0.00% | — | — | -45.83% | -195.82% | -42.68% | 0.00 | — | 10.22 | 10.03 | 1.18 | 3203.00% | -10000.00% | 8908.00% | -3.35% | -4.17 | -149.55% | 0.00% | 0.00% | 1.92% | -20.97 | -27.46 | — | 72.54 |
| SLNO | Soleno Therapeutics, Inc. | $39.07 | 2.1B | — | -51% | -73% | — | 99.43 | 4.61 | 10.91 | 62.51 | — | 4.66 | 98.58% | 7.85% | 10.97% | 6.01% | 19.44% | 4.67% | 0.01 | 2.73 | 5.80 | 5.44 | -2.38 | -10890.00% | — | -16741.00% | 2.25% | 0.76 | 60.75% | 0.00% | 0.00% | 6.38% | 118.68 | 37.97 | 9.32 | 10.94 |
| VKTX | Viking Therapeutics, Inc. | $33.84 | 3.91B | — | — | — | — | -10.44 | 5.88 | — | -7.76 | -4.84 | 5.88 | 0.00% | — | — | -47.34% | 896.45% | -44.29% | 0.00 | -7023.96 | 9.33 | 9.21 | 0.42 | 21584.00% | — | 21745.00% | -7.42% | -3.64 | 635.14% | 0.00% | 0.00% | 3.73% | -7.76 | -10.95 | — | 27.00 |
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- CEO
- Nello Mainolfi
- Employees
- 208
- Beta
- 2.22
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($42.98 ÷ $80.71) − 1 = -46.75% (DCF, example).